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Objective: Risk of venous thromboembolism (VTE) is increased in patients with hypo/
hyperthyroidism. It is unknown whether VTE may be a presenting symptom of occult cancer 
in these patients.
Design: Nationwide population-based cohort study based on Danish medical registry data.
Methods: We identified all patients diagnosed with VTE during 1978–2013 who had a previ-
ous or concurrent diagnosis of hypothyroidism (N=1481) or hyperthyroidism (N=1788). We 
followed them until a first-time cancer diagnosis, death, emigration, or study end, whichever 
came first. We calculated 1-year absolute cancer risk and standardized incidence ratios (SIRs) 
for cancer incidence in the study population compared with national cancer incidence in the 
general population.
Results: During the first year after a VTE diagnosis, the 1-year absolute cancer risk was 3.0% 
among patients with hypothyroidism and 3.9% among those with hyperthyroidism. During 
the first year of follow-up, SIRs for cancer in the study population compared with the general 
population were 1.96 (95% CI: 1.42–2.64) among patients with hypothyroidism and 2.67 (95% 
CI: 2.07–3.39) among those with hyperthyroidism. SIRs declined substantially after 1 year 
but remained increased during the remainder of the follow-up period (up to 36 years) (SIR for 
hypothyroidism=1.16 [95% CI: 0.97–1.39]; SIR for hyperthyroidism=1.26 [95% CI: 1.08–1.46]).
Conclusion: VTE may be a marker of underlying occult cancer in patients with hypothyroid-
ism or hyperthyroidism.
Keywords: hyperthyroidism, hypothyroidism, venous thromboembolism, cancer, cohort study
Introduction
Hyperthyroidism and hypothyroidism are common endocrine diseases, with estimated 
lifetime risks of 2%–5%.1,2 Hyperthyroidism is associated with biochemical changes 
consistent with vascular endothelial dysfunction and hypercoagulability – 2 of the 
3 factors that comprise Virchow’s triad of pathophysiological factors in thrombosis 
development.3,4 Moreover, hyperthyroidism is associated with reduced fibrinolytic 
activity.3,4 Accordingly, several cohort and case–control studies have reported up to a 
6-fold increased risk of venous thromboembolism (VTE) in patients with hyperthy-
roidism,5–10 with the increased VTE risk persisting for several years after diagnosis.5
The relation between hypothyroidism and coagulation disturbances is less clear. 
Some studies have noted bleeding tendencies and others have reported a hypercoagulable 
and hypofibrinolytic state.11 VTE risk in patients with hypothyroidism has been poorly 
investigated, with a single observational study reporting a 1.6-fold increased risk.12
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VTE is a well-known and frequent cancer complication.13 
Moreover, VTE occurrence may be the first sign of an as yet 
undiagnosed cancer.14–19 Previous studies have found a 2- to 
4-fold increased 1-year risk of cancer among patients diag-
nosed with VTE compared with the general population.14–18 
Initially, this was thought to be relevant only for primary or 
idiopathic VTE,19 that is, VTE occurring with no preceding 
risk factors, but increasing evidence suggests that occult 
cancer also may be a contributing cause in patients with 
secondary VTE.14
It is unknown whether VTE in patients with thyroid dis-
ease may be a marker of undiagnosed cancer. We, therefore, 
conducted this nationwide Danish population-based cohort 
study to compare cancer risk following VTE among patients 
with thyroid disease with that expected based on national 
cancer incidence.
Materials and methods
Setting and data sources
The Danish social welfare system provides tax-funded health 
care to the entire Danish population, with all provided ser-
vices registered in national health care databases. Accurate 
linkage of these databases is possible via the unique civil 
registration number (CPR number) assigned to each Danish 
resident at birth or upon emigration.20 The source population 
of the current cohort study consisted of the entire Danish 
population. During the 36-year study period (January 1, 1978 
to November 30, 2013), the cumulative population included 
8,096,820 persons.
Cohort of patients with VTE and thyroid 
disease
The Danish National Patient Registry (DNPR) contains 
information on all non-psychiatric inpatient admissions in 
Denmark since 1977. Hospital outpatient clinic visits and 
emergency room visits were added in 1995.21 Information 
recorded in the DNPR includes the CPR number, dates of 
admission and discharge, outpatient/emergency room visit 
dates, surgical procedures performed, and discharge diag-
noses classified according to the International Classification 
of Diseases, Eighth Revision through 1993 and Tenth Revi-
sion (ICD-10) thereafter.21 We used the DNPR to identify 
all patients with a first-time VTE (deep venous thrombosis 
of the lower limb or pulmonary embolism) diagnosed dur-
ing an inpatient admission or hospital outpatient clinic visit 
during the study period (N=156,387). Both primary and 
secondary discharge diagnoses were included. In Denmark, 
diagnoses of first-time VTE have a positive predictive value 
(PPV) higher than 80%.22 We excluded patients with VTEs 
diagnosed in the emergency room setting without a subse-
quent inpatient diagnosis, because of the low PPV (31%) 
of these  diagnoses.23 We also excluded all VTE patients 
who had a cancer diagnosis recorded at any time before or 
during the hospital contact with VTE (N=32,778). We then 
restricted our study cohort to VTE patients with a diagnosis 
of hypothyroidism (N=1481) or hyperthyroidism (N=1788) 
recorded at any time before or during the hospital contact 
in which the VTE was diagnosed. Patients with ICD-10 
codes for myxedema after treatment or thyrotoxicosis by 
overdose of thyroid hormone were excluded, because these 
patients could not clearly be assigned to either the hypo- or 
hyperthyroidism cohort. In the subgroup of VTE patients 
(N=226) who had both hypothyroidism and hyperthyroidism 
diagnoses recorded, the most recent pre-VTE thyroid disease 
diagnosis code determined membership in the hypothyroid-
ism vs hyperthyroidism subcohort. This was done to ensure 
that subcohort membership reflected thyroid hormone levels 
closest in time to the VTE date.
Cancer outcomes
We obtained information on cancers from the Danish Cancer 
Registry, which has recorded all incident cancers in Denmark 
since 1943, with information on morphology, histology, and 
cancer stage at diagnosis.24 We used the same grouping of 
cancers as presented in the Annual Cancer Report published 
by the Danish National Board of Health.
Covariates
The inpatient and outpatient hospital history available in the 
DNPR provided information on classic VTE risk factors in 
the 90-day period prior to VTE diagnosis (surgery, fractures/
trauma, and pregnancy), on obesity, and on diseases included 
in the Charlson Comorbidity Index (CCI).25,26 The CCI 
assigns 1–6 points to 19 disease categories according to their 
ability to predict short-term mortality. Based on total modi-
fied CCI scores (cancer excluded), we defined 3 categories 
of comorbidity burden: normal (0 points), moderate (1–2 
points), and high (3 or more points).
We obtained information on vital status from the Civil 
Registration System, which records data on death and migra-
tion with daily electronic updates.20
Relevant ICD codes and supporting information about 
grouping of cancers are provided in the online supplementary 
data (Table S1).
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Statistical analyses
We followed patients from VTE diagnosis until a cancer diag-
nosis, death, emigration, or study end, whichever occurred 
first. The follow-up period was split into 0–1 year and 1+ 
years. The first year was further divided into 0–90 days and 
91–365 days.
We calculated 1-year absolute cancer risks for all can-
cers, treating death as a competing risk.27 We calculated the 
expected cancer rate among patients with hypo/hyperthy-
roidism and VTE, assuming the expected cancer risk in this 
population would be the same as in the general population. 
We multiplied the number of person-years of observation 
by the Danish national cancer incidence rates across gender, 
single-year age groups, and single-year periods of diagnosis 
year to achieve the expected number of incident cancers. We 
then calculated the standardized incidence ratio (SIR), that is, 
the ratio of the observed to the expected number of cancers. 
This served as a measure of the relative risk of cancer in 
patients with thyroid disease and VTE. We calculated 95% 
CIs under the assumption that the observed number of cancers 
in a specific category followed a Poisson distribution.28 Exact 
95% CIs were used when the observed number of cancers 
was <10; otherwise, Byar’s approximation was used.28
Assuming that cancers detected during the first year fol-
lowing VTE also were present at the time of VTE diagnosis, 
we calculated the reciprocal of the excess risk ([observed 
number of cancers/follow-up time] – [expected number of 
cancers/follow-up time]) for the first year of follow-up, in 
order to determine the number needed to examine at time of 
VTE to detect 1 excess cancer.29 As well, 95% CIs were calcu-
lated as the reciprocal of the CIs for the excess risk estimate.30
In subgroup analyses, the results were stratified accord-
ing to age at VTE diagnosis, calendar-year period of VTE 
diagnosis (1978–1993 and 1994–2013), gender, comorbidity 
burden, obesity, and presence/absence of classic VTE risk 
factors.
In this study, we excluded all VTEs preceded by a can-
cer diagnosis. However, there may have been some delay 
in recording the cancer diagnosis. In addition, VTEs could 
have been detected coincidentally during diagnostic workup 
in patients suspected to have cancer. In order to examine 
the potential impact of including such VTEs in the analysis, 
the 90-day follow-up period was divided into 0–30 days 
and 31–90 days in sensitivity analyses. We also repeated 
all analyses after excluding cancers detected within the first 
30 days. Moreover, we repeated all analyses excluding the 
226 patients recorded as having both hypothyroidism and 
hyperthyroidism. Pharmacological or – for hyperthyroidism 
– surgical treatment may change hormone status to euthy-
roid. Therefore, we also conducted a sensitivity analysis in 
which we restricted the cohort to patients with a maximum 
2-year interval between their first hypo/hyperthyroid disease 
diagnosis and their first VTE diagnosis in order to increase 
the likelihood that our study population reflects patients with 
ongoing thyroid disease.
Statistical analyses were conducted using the SAS sta-
tistical software package, version 9.4 (SAS Institute, Cary, 
NC, USA). This study did not involve any patient contact or 
any intervention. Thus, approval from the Danish Scientific 
Ethical Committee and patient consent were not required. The 
study was approved by the Danish Data Protection Agency 
(record number 1-16-02-1-08).
Results
Descriptive data
We identified 1481 patients with hypothyroidism (86% 
female, median age: 75 years) and 1788 patients with 
hyperthyroidism (83% female, median age: 74 years) with 
a first-time VTE diagnosis (Table 1). Median time from first 
thyroid disease diagnosis to VTE diagnosis was 4.1 years 
(interquartile range [IQR]=0.6–10.0 years). The hypothy-
roidism subcohort was followed for a median of 2.5 years 
(IQR=0.4–6.1 years) and the hyperthyroidism subcohort was 
followed for a median of 2.6 years (IQR=0.3–6.6 years). In 
both subcohorts, 24%–25% of patients had classic risk factors 
and ≥78% of patients were diagnosed with VTE in the second 
half of the study period (1994–2013). Hospital-coded obesity 
was relatively uncommon (6%–11%) and was most prevalent 
among patients with hypothyroidism. Hospital-diagnosed 
comorbidity, defined as CCI points ≥1, was observed in 65% 
of patients with hypothyroidism and in 56% of those with 
hyperthyroidism.
Cancer data
During follow-up, 164 cancers were diagnosed among 
patients with hypothyroidism and 239 among those with 
hyperthyroidism. In the hypothyroidism subcohort, the 
1-year absolute cancer risk was 3.0%, corresponding to 
a 1-year cancer SIR of 1.96 (95% CI: 1.42–2.64). In the 
hyperthyroidism subcohort, the 1-year absolute cancer risk 
was 3.9%, corresponding to a 1-year cancer SIR of 2.67 
(95% CI: 2.07–3.39). Cancers were diagnosed most often 
within the first 90 days after a VTE diagnosis. In the hypo-
thyroidism subcohort, the 90-day cancer SIR was 2.36 (95% 
CI: 1.29–3.96), the 91–365 days SIR was 1.81 (95% CI: 
1.21–2.60), and the SIR during 1+ years of follow-up was 
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1.16 (95% CI: 0.97–1.39). A similar pattern was observed 
for the hyperthyroidism subcohort. However, the cancer 
risk within the first 90 days was even higher and the risk 
remained modestly increased beyond 1 year of follow-up. 
The 0–90 day cancer SIR was 5.32 (95% CI: 3.75–7.33), 
the 91–365 day cancer SIR was 1.68 (95% CI: 1.14–2.38), 
and the cancer SIR during 1+ years of follow-up was 1.26 
(95% CI: 1.08–1.46; Tables 2 and 3). The number of patients 
needed to examine in order to detect 1 excess cancer within 
the first year following VTE was 52 (95% CI: 32–142) in 
the hypothyroidism subcohort and 30 (95% CI: 22–49) in 
the hyperthyroidism subcohort.
Subgroup analyses
In the hypothyroidism subcohort, the 1-year cancer SIR was 
higher among patients who were younger and had a lower 
comorbidity burden. In contrast, the SIR showed only minor 
changes after stratification by gender, hospital-diagnosed 
obesity, calendar-year period, and presence/absence of classic 
VTE risk factors (Table 2).
In the hyperthyroidism subcohort, 1-year cancer SIRs 
varied modestly by age, comorbidity burden, gender, and 
calendar-year period (Table 3).
In the hypothyroidism subcohort, a 3-fold or greater 
increase was observed within the first year of follow-up for 
Table 1 Characteristics of patients with thyroid disease and a VTE, Denmark, 1978–2013
Hypothyroidism Hyperthyroidism
N (%) N (%)
Total 1481 (100) 1788 (100)
Female 1278 (86) 1480 (83)
Median age at VTE diagnosis (IQR), years 75 (65–82) 74 (64–82)
Age at VTE diagnosis
<60 years 259 (17) 326 (18)
60–74 years 488 (33) 598 (33)
75+ years 734 (50) 864 (48)
Comorbidity burdena
Normal 516 (35) 789 (44)
Medium 673 (45) 762 (43)
High 292 (20) 237 (13)
Charlson Comorbidity Index conditions
Myocardial infarction 167 (11) 158 (9)
Congestive heart failure 247 (17) 281 (16)
Peripheral vascular disease 145 (10) 172 (10)
Cerebrovascular disease 251 (17) 275 (15)
Dementia 56 (4) 46 (3)
Chronic pulmonary disease 302 (20) 312 (17)
Connective tissue disease 192 (13) 124 (7)
Gastrointestional ulcer 139 (9) 132 (7)
Mild liver disease 39 (3) 19 (1)
Diabetes 202 (14) 182 (10)
Hemiplegia 8 (1) 7 (0.4)
Moderate-to-severe renal disease 100 (7) 65 (4)
Diabetes with end-organ disease 103 (7) 84 (5)
Moderate-to-severe liver disease 7 (1) 3 (0.2)
AIDS 0 (0) 0 (0)
Year of VTE diagnosis
1978–1993 318 (21) 397 (22)
1994–2011 1,163 (79) 1,391 (78)
Obesity 163 (11) 108 (6)
Provoking factorsb
Classic provoking factors, overall 371 (25) 424 (24)
Surgery 293 (20) 341 (19)
Trauma/fracture 136 (9) 171 (10)
Pregnancy 5 (0.3) 4 (0.2)
Notes: aThree categories of comorbidity burden based on the Charlson Comorbidity Index; normal=0 points, moderate=1–2 points, and high=3 or more points. Cancer was 
excluded from the comorbidity index. bWithin the 3 months prior to a VTE diagnosis.
Abbreviations: IQR, interquartile range; VTE, venous thromboembolism; AIDS, acquired immune deficiency syndrome.
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cancers of the ovary and for non-Hodgkin malignant lym-
phoma. In the hyperthyroidism subcohort, corresponding 
increases were observed for cancers of the large intestine, 
pancreas, uterine cervix, uterus, ovary, prostate, and urinary 
bladder, as well as for non-specified cancers and metastases 
(Tables S2 and S3).
Sensitivity analyses
Within 30 days following the VTE diagnosis date, 8 cancers 
were diagnosed in the hypothyroidism subcohort and 27 
in the hyperthyroidism subcohort. The 30-day SIRs were 
3.91 (95% CI: 1.69–7.70) and 11.10 (95% CI: 7.32–16.16), 
respectively, in the 2 subcohorts (Tables S4 and S5). Exclud-
ing these cancers, the 1-year SIR decreased to 1.76 (95% 
CI: 1.23–2.45) in the hypothyroidism subcohort and to 1.78 
(95% CI: 1.28–2.42) in the hyperthyroidism subcohort. 
(Tables S6 and S7). Excluding the 226 patients with both 
hypo- and hyperthyroid diagnosis did not change the results 
(data not shown). Restricting the cohort to patients with 
a maximum interval of 2 years from hypo/hyperthyroid 
diagnosis to VTE diagnosis had no significant effect on the 
results for the hypothyroidism subcohort (Tables S8–S10). 
For the hyperthyroidism subcohort, the SIRs, in general, 
increased, except for the 91–365 days period; 0–90 days SIR: 
8.27 (95% CI: 4.90–13.08), 91–365 days SIR: 1.36 (95% 
CI: 0.59–2.68), 1-year SIR: 3.22 (95% CI: 2.11–4.72), and 
SIR during 1+ years of follow-up: 1.54 (95% CI: 1.22–1.91; 
Tables S11–S13). However, precision was reduced in these 
sensitivity analyses.
Discussion
In this large population-based cohort study, we evaluated the 
association between VTE occurrence and subsequent cancer 
diagnoses in patients with hypo/hyperthyroidism. We found 
an absolute cancer risk of 3.0%–3.9% in the first year follow-
ing VTE and a relative cancer risk of 2.0–2.7 compared with 
the general population. The relative risk of cancer declined 
after the first year of follow-up, suggesting that development 
of a VTE can be regarded as a potential early manifestation 
of an underlying malignancy among patients with hypo/
hyperthyroid disease.
Our study adds to the literature on VTE and cancer by 
clarifying the association for patients with hypo/hyperthy-
roidism, in whom thyroid disease itself may cause coagula-
tion disturbances and increase VTE risk, independent of 
underlying cancer. Similar to previous studies in the general 
population, we observed the highest increase in cancer risk 
immediately after VTE diagnosis, followed by a decline.14,16–18 
One-year SIRs in our study were consistent with the 2- to 
4-fold increased cancer risk observed in studies of VTE in 
the general population.14–18
The persistent but modest increase in cancer risk beyond 
1 year of follow-up also has been observed for VTE patients 
in general14,16–18 and may be explained by common shared 
lifestyle risk factors for VTE and cancer, such as smoking, 
obesity, or hormone replacement therapy, or by premalig-
nant changes that promote thrombosis.17 Another possible 
explanation for our results is the putative oncogenic effects 
of thyroid hormones.31
Awareness of the association between VTE and cancer 
may lead to heightened diagnostic efforts. This is suggested 
by the higher SIRs observed in the later calendar-year period. 
However, a period of increased cancer risk then would have 
been followed by a compensatory deficit,17 which was not 
observed. This implies that detection bias does not explain 
our results.
The number of patients needed to examine to detect 1 
excess cancer within the first year after VTE was only 30 in 
the hyperthyroidism subcohort and 52 in the hypothyroidism 
subcohort. However, the clinical utility of extensive screening 
for cancer in VTE patients depends on the ability to detect 
the cancer using these methods, as well as on the prognostic 
impact of earlier cancer detection. These topics were not 
investigated in this study. Cancers preceded by VTE have a 
higher stage at diagnosis and a worse prognosis compared 
with other cancers.32 Previous studies have not provided 
strong evidence that extensive screening to detect occult 
cancer after VTE improves patient prognosis.33–36 Moreover, 
extensive screening for cancer may be associated with physi-
cal and psychological discomfort.37
Still, detection of an underlying cancer may have implica-
tions for VTE management, including treatment of the VTE.38 
We, thus, concur that patients with hypo/hyperthyroidism 
and VTE undergo diagnostic workup for cancer to the same 
extent as non-thyroid patients diagnosed with VTE.
The validity of our results depends on several factors. 
Major study strengths are its nationwide population-based 
design and completeness of patient follow-up, which reduced 
the risk of selection bias. As the DNPR covers all hospital 
contacts in Denmark, the study was not affected by selective 
inclusion of specific hospitals, health insurance systems, or 
age groups. As well, the validity of data on VTE,22 thyroid 
disease,39 cancer,40 and comorbidities41 is high.
Study limitations include the potential for protopathic 
bias, that is, cancer diagnostic activities leading to a VTE 
diagnosis. Moreover, in some cases, the registration of a 
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 cancer diagnosis might be delayed compared with a con-
comitant VTE diagnosis. However, in our study, an increased 
cancer risk was still observed after excluding cancers detected 
within 30 days post-VTE. Our cancer site-specific results 
should be interpreted with caution since analysis of the high-
risk cancer sites were based on small numbers of cancers, 
limiting statistical precision. We lacked drug utilization data 
and could, therefore, not stratify our cancer analyses of thy-
roid disease patients by use of VTE-associated drugs. Finally, 
we lacked biochemical data and thus, could not evaluate the 
association between VTE and cancer stratified by thyroid 
hormone levels. This may be relevant since some studies 
have indicated that coagulation disturbances in patients 
with thyroid disease become more marked with increasing 
deviation of thyroid hormone levels from the normal range.6,8 
However, restricting our cohort to patients with a more recent 
thyroid disease diagnosis did not change the results for the 
hypothyroidism subcohort. For the hyperthyroidism subco-
hort, the SIRs increased rather than decreased, as would be 
expected if the hormone disturbances caused more VTEs.
Conclusion
In conclusion, VTE is a multicausal disease and our findings 
suggest that among patients with hypothyroidism or hyper-
thyroidism, VTE also may be a marker of underlying cancer, 
consistent with observations in the general population. Thus, 
our results support that patients with hypo/hyperthyroidism 
and VTE undergo diagnostic workup for cancer to the same 
extent as non-thyroid patients diagnosed with VTE.
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